MichaelJTolentinoMD

Ophthalmology • Clearwater, FL

Retinal Disease

Physician

Join to view full profile

Dr. Tolentino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tolentino's full profile

Already have an account?

Office
3280 N McMullen Booth Rd
Ste 120
Clearwater, FL 33761
Phone+1 727-789-8770

Fax+1 727-789-8784

Education & Training

Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1994 - 1999
Mount Auburn HospitalInternship, Internal Medicine, 1993 - 1994
University of Massachusetts Medical SchoolClass of 1993

Certifications & Licensure

FL State Medical License 2004 - 2025
MA State Medical License 1998 - 2005
PA State Medical License 1999 - 2004
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion Start of enrollment: 2014 Feb 01
Completed
Phase 2
Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older Start of enrollment: 2014 May 01
Completed
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD Start of enrollment: 2015 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

3 citations
PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular ...
Sheri L Peterson, Anitha Krishnan, Diyan Patel, Ali Khanehzar, Amit Lad
Pharmaceuticals. 2024-04-17
1 citations
Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-...
Anitha Krishnan, David G Callanan, Victor G Sendra, Amit Lad, Sunny Christian
Pharmaceuticals. 2024-04-09
2 citations
Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Relat...
Michael J Tolentino, Andrew J Tolentino, Elizabeth M Tolentino, Anitha Krishnan, Mohamed A Genead
Pharmaceuticals. 2023-12-16

Press Mentions

Aviceda Therapeutics : Announces Strategic Alliance with University of GeorgiaSeptember 27th, 2021
Aviceda Therapeutics Announces Formation of Executive TeamJanuary 11th, 2021
Michael J. Tolentino, MD, Ophthalmologist, Retinal Specialist – Surgeon with the Macula CenterMay 13th, 2019
Join now to see all

Grant Support

Mechanism Of Mutant TIMP-3 Induced NeovascularizationNational Eye Institute2001–2004

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow